International Kidney Cancer Symposium (IKCS) 2021

The International Kidney Cancer Symposium (IKCS) 2021 took place in North America over the weekend. The following presentations are of interest to kidney cancer patients and their families and are published by UroToday: Award lecture: Dr Brian Lane gave the Andrew C. Novick Award Lecture with a talk focusing on the management of small (T1) […]

read more

SMC approves cabozantinib/nivolumab combination for advanced kidney cancer in Scotland

The Scottish Medicines Consortium (SMC) has approved the use of the combination of cabozantinib (a vascular endothelial growth factor (VEGF) inhibitor) plus nivolumab (an immunotherapy) for use by NHS Scotland for the treatment of untreated people with advanced renal cell carcinoma (RCC). The approval was based on the results from a phase 3 study, which […]

read more

Pegilodecakin for metastatic kidney cancer

Combinations of immunotherapy and vascular endothelial growth factor (VEGF) inhibitors have been proven to effective at improving survival for people with advanced or metastatic renal cell carcinoma (RCC). However, the role of a cytokine called interleukin-10 (IL-10) has been shown to enhance immunotherapy-induced anti-cancer activity. In this phase 1 trial, the safety, tolerability and preliminary […]

read more

ASCO 2021: Cobozantinib plus nivolumab combination for non-clear cell kidney cancer

The cabozantinib/nivolumab combination has been shown to be effective at improving survival in patients with metastatic clear cell renal cell carcinoma (RCC) in a phase 3 trial. This study, presented at the American Society for Clinical Oncology (ASCO) Annual Meeting held virtually over the weekend reports the results of a phase 2 trial of cabozantinib/nivolumab […]

read more

EIKCS 2021: Future treatments for metastatic kidney cancer

Despite the advances in first-line treatments for metastatic renal cell carcinoma (RCC) over the past few years, new treatments are on the horizon. In a presentation at the European International Kidney Cancer (EIKC) 2021 Virtual Annual Meeting, Dr Hans Hammers from University of Texas Southwestern Medical Center in the USA discussed future treatments for metastatic […]

read more

EIKCS 2021: Second-line and later treatments for metastatic kidney cancer

The increase in the number of first-line treatments for metastatic renal cell carcinoma (RCC) over the past 3 years has had meaningful effects on the choice of second-line treatments. Dr Camillo Porta from the University of Pavia in Italy discussed the selection of second-line and later treatments in a presentation at the European International Kidney […]

read more

EIKCS 2021: Combination therapies for metastatic kidney cancer: Which Approach?

The use of combination therapies for the first-line treatment of metastatic renal cell carcinoma (RCC) has increased significantly over the past 3 years. However, there are now a number of potential first-line treatments, and choosing the most suitable treatment for each individual patient can be difficult. In a presentation at the European International Kidney Cancer […]

read more

Effectiveness of second-line sunitinib after immunotherapy in metastatic kidney cancer

There is very little information on the effectiveness of sunitinib (a vascular endothelial growth factor (VEGF) inhibitor) as a second-line treatment after first-line treatment with immunotherapy for patients with metastatic renal cell carcinoma (RCC). A study published in Clinical Genitourinary Cancer last month looked at 102 patients in a real-world setting who were treated with […]

read more

Longer term outcomes with pembrolizumab plus axitinib combination for advanced kidney cancer

This Practice Update interview with Dr Monty Pal from City of Hope Hospital, Duarte, USA and Dr Jun Gong from Cidars-Sinai Medical Centre, Los Angeles, USA reports further follow-up data from the KEYNOTE-426 clinical trial. KEYNOTE-426 is a phase 3 trial looking at the effectiveness of a combination of axitinib and pembrolizumab compared to sunitinib […]

read more

ASCO GU 2021: Outcomes of first-line immunotherapy combinations in metastatic kidney cancer

Combinations of immunotherapy drugs nivolumab plus ipilimumab and immunotherapy/vascular endothelial growth factor (VEGF) inhibitors are widely used for the treatment of metastatic renal cell carcinoma (RCC). However, limited information is available to compare the outcomes from different combinations. At the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) over the weekend, data […]

read more
Showing 1 to 10 of 67 results
  TOP